Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep 28:8:79.
doi: 10.1186/1476-4598-8-79.

Discovery and identification of potential biomarkers of papillary thyroid carcinoma

Yuxia Fan  1 , Linan Shi, Qiuliang Liu, Rui Dong, Qian Zhang, Shaobo Yang, Yingzhong Fan, Heying Yang, Peng Wu, Jiekai Yu, Shu Zheng, Fuquan Yang, Jiaxiang Wang
Affiliations

Discovery and identification of potential biomarkers of papillary thyroid carcinoma

Yuxia Fan et al. Mol Cancer. .

Abstract

Background: Thyroid carcinoma is the most common endocrine malignancy and a common cancer among the malignancies of head and neck. Noninvasive and convenient biomarkers for diagnosis of papillary thyroid carcinoma (PTC) as early as possible remain an urgent need. The aim of this study was to discover and identify potential protein biomarkers for PTC specifically.

Methods: Two hundred and twenty four (224) serum samples with 108 PTC and 116 controls were randomly divided into a training set and a blind testing set. Serum proteomic profiles were analyzed using SELDI-TOF-MS. Candidate biomarkers were purified by HPLC, identified by LC-MS/MS and validated using ProteinChip immunoassays.

Results: A total of 3 peaks (m/z with 9190, 6631 and 8697 Da) were screened out by support vector machine (SVM) to construct the classification model with high discriminatory power in the training set. The sensitivity and specificity of the model were 95.15% and 93.97% respectively in the blind testing set. The candidate biomarker with m/z of 9190 Da was found to be up-regulated in PTC patients, and was identified as haptoglobin alpha-1 chain. Another two candidate biomarkers (6631, 8697 Da) were found down-regulated in PTC and identified as apolipoprotein C-I and apolipoprotein C-III, respectively. In addition, the level of haptoglobin alpha-1 chain (9190 Da) progressively increased with the clinical stage I, II, III and IV, and the expression of apolipoprotein C-I and apolipoprotein C-III (6631, 8697 Da) gradually decreased in higher stages.

Conclusion: We have identified a set of biomarkers that could discriminate PTC from non-cancer controls. An efficient strategy, including SELDI-TOF-MS analysis, HPLC purification, MALDI-TOF-MS trace and LC-MS/MS identification, has been proved successful.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A representative mapping of SELDI-TOF-MS analysis of sera from PTC patients and healthy controls. Differentially expressed proteins with potential diagnostic significance are arrowed. Top-group denotes sera from patients with PTC, in which the protein with m/z of 9190 Da was over-expressed. Bottom-group denotes sera from healthy individuals, in which the proteins with m/z of 6631 and 8697 Da were up-regulated.
Figure 2
Figure 2
A representative mapping of SELDI-TOF-MS analysis from different stages of PTC patients and non-cancer controls. The level of the 9190 Da protein progressively increased with the clinical stage I, II, III and IV, and the expression of 6631 and 8697 Da proteins gradually decreased in higher stages.
Figure 3
Figure 3
MALDI-TOF-MS spectra of three purified potential protein markers.
Figure 4
Figure 4
Results of the identification of protein (8697 Da) by LC-MS/MS. (A) Chromatogram of peptide mixture. (B) MS/MS spectrum of one peptide.
Figure 5
Figure 5
Representative spectra from ProteinChip array with specific immobilized antibodies. (A) Representative spectra of the negative control (nonspecific rabbit IgG). (B) Representative spectra from ProteinChip array with anti-haptoglobin alpha chain antibody. (C) Representative spectra from ProteinChip array with anti-apolipoprotein C-I. (D) Representative spectra from ProteinChip array with anti-apolipoprotein C-III.
See this image and copyright information in PMC

References

    1. Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer. 2005;117:281–288. doi: 10.1002/ijc.21064. - DOI - PubMed
    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. doi: 10.3322/CA.2007.0010. - DOI - PubMed
    1. Pelizzo MR, Merante Boschin I, Toniato A, Casal Ide E, Mian C, Rubello D, Pagetta C. Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma. Minerva Endocrinol. 2008;33:359–379. - PubMed
    1. Hayashi N, Kitaoka M. Fine-needle aspiration biopsy of the thyroid nodule: uses and limitations. Nippon Rinsho. 2007;65:2003–2007. - PubMed
    1. Inohara H, Segawa T, Miyauchi A, Yoshii T, Nakahara S, Raz A, Maeda M, Miyoshi E, Kinoshita N, Yoshida H, Furukawa M, Takenaka Y, Takamura Y, Ito Y, Taniguchi N. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochem Biophys Res Commun. 2008;376:605–610. doi: 10.1016/j.bbrc.2008.09.041. - DOI - PubMed

Publication types

MeSH terms